⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SRXH News
SRX Health Solutions, Inc.
SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics’ Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies
globenewswire.com
SRXH
CERO
SRX Global Commits $2.5 Million to Launch Multi-Strategy Trading Platform in Partnership with 5T Trading, Powered by the EMJX Platform
globenewswire.com
SRXH
SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies
globenewswire.com
SRXH
CERO
Form 8-K
sec.gov
SRXH
SRX Global Commits $1.5 Million to Launch Family of AI-Powered ETFs through its EMJX Platform, Partnering with Kupa AI Co-Founder Andy Kim
globenewswire.com
SRXH
Form 8-K
sec.gov
SRXH
SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)
globenewswire.com
ONCO
SRXH
VTGN
GRML
SRX Global CEO Kent Cunningham and President of EMJX Platform Eric Jackson to Present at Webull Corporate Connect Series Fintech Investment Webinar
globenewswire.com
SRXH
Form 8-K
sec.gov
SRXH
SRX Global Provides Shareholder Update on Portfolio Company, ARMR Sciences, a Clinical-Stage Biodefense Company
globenewswire.com
SRXH